Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apc-100. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | TTPA | P49638 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134532 | 0.79 | GSTO1 (0.57) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL5796169 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL5774935 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL5772272 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL13832490 | 0.77 | PTGS1 (0.48) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL14950827 | 0.77 | PTGS1 (0.76) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL5773655 | 0.77 | PTGS1 (0.48) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL2059274 | 0.77 | PTGS1 (0.76) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL4427867 | 0.77 | CYP3A4 (0.62) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL14283899 | 0.76 | CYP3A4 (0.47) | CYP3A4TSHRPTGS1PTGS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703417-B2 | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8329401-B2 | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120283141-A1 | ENZYME-CATALYZED METAL DEPOSITION FOR THE ENHANCED DETECTION OF ANALYTES OF INTEREST | VENTANA MEDICAL SYSTEMS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20100105566-A1 | Enzyme-Catalyzed Metal Deposition for the Enhanced Detection of Analytes of Interest | VENTANA MEDICAL SYSTEMS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7642064-B2 | Binding enzyme-labeled conjugate (antibodies, haptens with phospatases, galactosidases, beta-glucosidases, esterases, and beta-lactamases) to epitope/sequence in presence of redox-inactive reductive species and soluble gold/silver ion; solid phase synthesis; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7632652-B2 | Binding enzyme-labeled conjugate (antibodies, haptens with phospatases, galactosidases, beta-glucosidases, esterases, and beta-lactamases) to epitope/sequence in presence of redox-inactive reductive species and soluble gold/silver ion; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1636586-B1 | ENZYME-CATALYZED METAL DEPOSITION FOR THE ENHANCED IN SITU DETECTION OF IMMUNOHISTOCHEMICAL EPITOPES AND NUCLEIC ACID SEQUENCES | VENTANA MED SYST INC (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1636586-A2 | ENZYME-CATALYZED METAL DEPOSITION FOR THE ENHANCED IN SITU DETECTION OF IMMUNOHISTOCHEMICAL EPITOPES AND NUCLEIC ACID SEQUENCES | VENTANA MEDICAL SYSTEMS, INC. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050100976-A1 | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest | VENTANA MEDICAL SYSTEMS, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005003777-A2 | ENZYME-CATALYZED METAL DEPOSITION FOR THE ENHANCED IN SITU DETECTION OF IMMUNOHISTOCHEMICAL EPITOPES AND NUCLEIC ACID SEQUENCES | VENTANA MEDICAL SYSTEMS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040265922-A1 | Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences | VENTANA MEDICAL SYSTEMS, INC. | 2004-12-30 | — | — | US | disclosed |